FoxO3 an Important Player in Fibrogenesis (IMAGE) Max-Planck-Gesellschaft Caption New therapeutic approach to treating idiopathic pulmonary fibrosis. A key factor in the development of the disease is low levels of activity of the FoxO3 transcription factor. Experiments on mice have shown that treatment with UCN-01 stops progression of the disease and even reduces symptoms. The illustration shows a schematic representation of a diseased and a healed lung (top), and tissue preparations from the lung of a mouse with idiopathic pulmonary fibrosis (left) and a mouse after treatment with UCN-01 (right). Credit MPI f. Heart and Lung Research Usage Restrictions Use of images is limited to editorial coverage of scientific topics relating to the activities of the Max Planck Society. Any kind of commercial use (including, in particular, the exploitation of images by means of sale or incorporation in image databases or image catalogues) as well as any promotional use/use for merchandise purposes, disclosure to third parties or granting of related rights to third parties is expressly not permitted. License Licensed content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.